Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

STAAR Surgical Company

Healthcare US STAA

17.23USD
-1.09(5.95%)

Last update at 2026-03-10T20:00:00Z

Day Range

17.0618.57
LowHigh

52 Week Range

26.6659.24
LowHigh

Fundamentals

  • Previous Close 18.32
  • Market Cap2011.43M
  • Volume1193241
  • P/E Ratio132.06
  • Dividend Yield-%
  • EBITDA29.88M
  • Revenue TTM326.24M
  • Revenue Per Share TTM6.70
  • Gross Profit TTM 223.38M
  • Diluted EPS TTM0.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax 45.80M 31.30M 8.27M 13.03M 6.64M
Minority interest - - - - -
Net income 39.01M 24.50M 5.91M 14.05M 4.97M
Selling general administrative 54.74M 44.14M 33.91M 29.31M 24.29M
Selling and marketing expenses 88.86M 67.29M 45.76M 45.49M 38.60M
Gross profit 223.38M 178.64M 118.36M 111.95M 91.51M
Reconciled depreciation 4.51M 3.64M 3.10M 3.70M 2.46M
Ebit 43.80M 33.34M 6.77M 11.85M 7.43M
Ebitda 50.02M 39.95M 9.00M 16.07M 9.89M
Depreciation and amortization 6.22M 6.61M 2.23M 4.22M 2.46M
Non operating income net other - - 1.26M 0.19M -0.12100M
Operating income 43.80M 33.34M 6.77M 11.85M 6.59M
Other operating expenses 240.59M 197.13M 156.69M 138.33M 117.36M
Interest expense 2.45M -0.00004M 2.36M 0.66M 0.17M
Tax provision 6.80M 6.80M 2.35M -1.02200M 1.67M
Interest income - - 0.24M - -
Net interest income 2.45M -0.03800M 0.24M 0.99M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 6.80M 6.80M 2.35M -1.02200M 1.67M
Total revenue 284.39M 230.47M 163.46M 150.19M 123.95M
Total operating expenses 179.58M 145.30M 111.59M 100.10M 84.92M
Cost of revenue 61.01M 51.84M 45.10M 38.23M 32.44M
Total other income expense net 2.00M -2.03500M 1.50M 1.17M -0.12100M
Discontinued operations - - - - -
Net income from continuing ops 39.01M 24.50M 5.91M 14.05M 4.97M
Net income applicable to common shares 38.76M 24.50M 5.91M 14.05M 4.97M
Preferred stock and other adjustments - - - - -
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 488.69M 415.15M 345.78M 257.42M 206.87M
Intangible assets - 0.17M 0.22M 0.27M 0.30M
Earning assets - - - - -
Other current assets 11.43M 13.73M 10.90M 0.69M 0.32M
Total liab 102.74M 82.71M 87.22M 60.19M 46.98M
Total stockholder equity 385.95M 332.44M 258.56M 197.22M 159.88M
Deferred long term liab - - - 0.22M -
Other current liab 36.26M 36.45M 31.88M 24.61M 17.70M
Common stock 0.49M 0.48M 0.48M 0.46M 0.45M
Capital stock 0.49M 0.48M 0.48M 0.46M 0.45M
Retained earnings -47.36800M -72.38500M -111.39000M -135.89100M -141.80400M
Other liab - 3.64M 9.77M 12.38M 8.05M
Good will 1.79M 1.79M 1.79M 1.79M 1.79M
Other assets - 5.78M 4.63M 5.55M 4.50M
Cash 183.04M 86.48M 199.71M 152.45M 119.97M
Cash and equivalents - - - - -
Total current liabilities 65.04M 51.72M 48.80M 41.24M 34.48M
Current deferred revenue 10.85M - 4.82M 4.53M 3.64M
Net debt -147.20400M -55.44100M -167.64500M -141.65400M -110.42900M
Short term debt 4.37M 3.69M 3.41M 4.22M 5.09M
Short long term debt - - - 1.38M 1.83M
Short long term debt total 35.83M 31.04M 32.06M 10.80M 9.54M
Other stockholder equity 436.95M 404.19M 373.52M 338.19M 304.29M
Property plant equipment - 81.53M 67.73M 24.03M 17.07M
Total current assets 365.27M 311.97M 271.41M 216.42M 174.67M
Long term investments 11.70M 13.90M - - -
Net tangible assets - 330.23M 256.55M 195.17M 157.80M
Short term investments 37.69M 125.16M - - -
Net receivables 97.98M 62.45M 43.53M 35.23M 31.00M
Long term debt - - - - -
Inventory 35.13M 24.16M 17.27M 18.11M 17.14M
Accounts payable 13.56M 11.58M 8.70M 7.87M 8.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.11300M 0.16M -4.04800M -5.54500M -3.04800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.46M 0.45M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -135.89100M -141.80400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.34M 0.96M 0.82M 0.61M 0.75M
Deferred long term asset charges - - - - 3.75M
Non current assets total 123.42M 103.17M 74.37M 41.00M 32.20M
Capital lease obligations 35.83M 31.04M 32.06M 9.42M 7.71M
Long term debt total - - - - 0.37M
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Investments 74.35M -156.37600M -13.64500M -8.40400M -10.17800M
Change to liabilities - 1.80M 0.11M 7.01M 5.88M
Total cashflows from investing activities - -156.37600M -13.64500M -8.40400M -10.17800M
Net borrowings - -0.12600M -1.64500M -0.51500M -2.01800M
Total cash from financing activities 7.42M 8.30M 17.79M 19.57M 0.15M
Change to operating activities - -3.14000M 6.30M 3.41M 3.12M
Net income 21.35M 39.01M 24.50M 5.91M 14.05M
Change in cash 96.56M -113.22600M 47.25M 32.48M 15.97M
Begin period cash flow 86.48M 199.71M 152.45M 119.97M 104.00M
End period cash flow 183.04M 86.48M 199.71M 152.45M 119.97M
Total cash from operating activities 14.59M 35.72M 43.96M 20.95M 25.80M
Issuance of capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00200M
Depreciation 5.12M 4.51M 3.64M 3.10M 3.70M
Other cashflows from investing activities - - - - -0.08300M
Dividends paid 0.00967M - - - -
Change to inventory -14.36100M -7.94300M 0.07M -1.39000M -0.95000M
Change to account receivables -32.76000M -19.60100M -8.86800M -3.97400M -4.50200M
Sale purchase of stock -2.09700M 0.00000M 0.00000M 20.65M 3.46M
Other cashflows from financing activities 0.00967M 8.42M 19.44M 20.13M 0.00200M
Change to netincome - 21.28M 18.21M 14.05M 8.94M
Capital expenditures 18.19M 18.11M 13.64M 8.40M 10.18M
Change receivables - - - -3.97400M -4.50200M
Cash flows other operating - - - -3.75300M -1.31300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 32.12M 15.77M
Change in working capital -40.83900M -29.12800M -2.39200M -2.76400M -1.24600M
Stock based compensation 23.52M 20.37M 14.61M 12.15M 10.55M
Other non cash items 2.18M 2.30M 2.11M 3.41M 2.23M
Free cash flow -3.59400M 17.61M 30.32M 12.55M 15.62M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
STAA
STAAR Surgical Company		 -1.09 5.95% 17.23 132.06 175.44 7.55 6.30 6.97 67.67
ISRG
Intuitive Surgical Inc		 -7.71 1.56% 485.85 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 -0.25 0.20% 122.50 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 4.90 2.00% 249.71 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 -1.58 0.95% 163.88 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Company

25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630

Key Executives

Name Title Year Born
Ms. Caren L. Mason CEO, Pres & Director 1954
Mr. Patrick F. Williams Chief Financial Officer 1973
Dr. Keith Holliday Chief Technology Officer 1963
Mr. Hans-Martin Blickensdoerfer Consultant 1965
Dr. Scott D. Barnes M.D. Chief Medical Officer 1963
Mr. Brian Moore VP of Investor, Media Relations & Corp. Devel. NA
Mr. Samuel J. Gesten Chief Legal Officer & Corp. Sec. 1962
Mr. James Francese Sr. VP of Commercial Operations - North America & APAC 1964
Joanne Egamino Ph.D. Global Head of Clinical Operations NA
Mr. Philippe Subrin VP of Collamer Lens Manufacturing & GM of Nidau Operations 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.